Cite
The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer.
MLA
Padmakar Darne, Chetan, et al. “The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer.” Bioorganic & Medicinal Chemistry Letters, vol. 75, Nov. 2022, p. N.PAG. EBSCOhost, https://doi.org/10.1016/j.bmcl.2022.128951.
APA
Padmakar Darne, C., Velaparthi, U., Saulnier, M., Frennesson, D., Liu, P., Huang, A., Tokarski, J., Fura, A., Spires, T., Newitt, J., Spires, V. M., Obermeier, M. T., Elzinga, P. A., Gottardis, M. M., Jayaraman, L., Vite, G. D., & Balog, A. (2022). The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer. Bioorganic & Medicinal Chemistry Letters, 75, N.PAG. https://doi.org/10.1016/j.bmcl.2022.128951
Chicago
Padmakar Darne, Chetan, Upender Velaparthi, Mark Saulnier, David Frennesson, Peiying Liu, Audris Huang, John Tokarski, et al. 2022. “The Discovery of BMS-737 as a Potent, CYP17 Lyase-Selective Inhibitor for the Treatment of Castration-Resistant Prostate Cancer.” Bioorganic & Medicinal Chemistry Letters 75 (November): N.PAG. doi:10.1016/j.bmcl.2022.128951.